Vseobecna Fakultni Nemocnice V Praze
- Address
- lock Available on a paid plan
Respiratory and Pediatric Allergy Research
At Vseobecna Fakultni Nemocnice V Praze, clinical trials in respiratory tract diseases focus on asthma in children, with an emphasis on improving symptom control and lung function through new treatment options.
- Evaluating whether newer inhaled therapies can improve breathing outcomes in pediatric asthma
- Comparing treatment effectiveness to support better long-term disease management
This area of research aims to strengthen care for young patients living with chronic airway disease.
Inflammatory Bowel Disease Studies
The site also supports research in immune system diseases and digestive system disorders, especially Crohn's disease in children and adolescents, with trials designed to assess how well emerging therapies work and how safe they are.
- Testing treatments for moderately to severely active pediatric Crohn's disease
- Assessing treatment response in patients who have not benefited from standard therapies
These studies help advance care for young people facing persistent intestinal inflammation.
Rare Genetic and Growth Disorder Research
Research in congenital, hereditary, and neonatal diseases at this Prague hospital includes studies in osteochondrodysplasia, particularly achondroplasia, with a focus on safety and early treatment evaluation.
- Studying therapies for children with rare skeletal growth disorders
- Exploring whether new approaches may support better disease management and functional outcomes
This work reflects a strong interest in rare pediatric conditions and inherited disorders.
Broader Immune and Developmental Research
Beyond the main diseases studied, the clinical program covers immune system processes and related pediatric conditions, showing a broad interest in how inflammation and development affect child health.
- Investigating therapies that may improve control of immune-mediated disease
- Supporting research into pediatric conditions with complex developmental and inflammatory features
With a large investigator base, the department contributes to a diverse portfolio of clinical research in children.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 25 therapeutic areas and 15 of 547 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 530 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 96 by active trials.
- 1Novartis Pharma AG14active
lock +95 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG26trials
lock +50 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vseobecna Fakultni Nemocnice V Praze
lock Showing 1 of 379 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 547 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 28 | Unknown | 2017-12-14 | 2026-03-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.